COVID-19 and Special Populations

Last Updated: October 9, 2020

Key Considerations

<table>
<thead>
<tr>
<th>There is current guidance from the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal-Fetal Medicine (SMFM) on the management of pregnant patients with COVID-19.¹⁻⁴ This section of the COVID-19 Treatment Guidelines complements that guidance. Below are key considerations regarding the management of COVID-19 in pregnancy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Pregnant women should be counseled about the potential for severe disease from SARS-CoV-2 infection and the recommended measures to take to protect themselves and their families from infection.</td>
</tr>
<tr>
<td>• If hospitalization for COVID-19 is indicated in a pregnant woman, care should be provided in a facility that can conduct maternal and fetal monitoring, when appropriate.</td>
</tr>
<tr>
<td>• Management of COVID-19 in the pregnant patient should include:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>• The COVID-19 Treatment Guidelines Panel (the Panel) recommends that potentially effective treatment for COVID-19 should not be withheld from pregnant women because of theoretical concerns related to the safety of therapeutic agents in pregnancy (AII).</td>
</tr>
<tr>
<td>• Decisions regarding the use of drugs approved for other indications or investigational drugs for the treatment of COVID-19 in pregnant patients must be made with shared decision-making between the patient and the clinical team, considering the safety of the medication for the pregnant woman and the fetus and the severity of maternal disease. For detailed guidance on the use of COVID-19 therapeutic agents in pregnancy, please refer to the pregnancy considerations subsection of each individual section of the Guidelines.</td>
</tr>
</tbody>
</table>

Rating of Recommendations: A = Strong; B = Moderate; C = Optional

Rating of Evidence: I = One or more randomized trials without major limitations; Ila = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

To date, most of the data generated about the epidemiology, clinical course, prevention, and treatment of COVID-19 have come from studies of nonpregnant adults. More information is urgently needed regarding COVID-19 in other patient populations, such as in children, pregnant individuals, and other populations as outlined in the following sections of the Guidelines.

Although children with COVID-19 may have less severe disease overall than adults with COVID-19, the recently described multisystem inflammatory syndrome in children (MIS-C) requires further study. Data are also emerging on the clinical course of COVID-19 in pregnant patients, pregnancy outcomes in the setting of COVID-19, and vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There are special considerations for transplant recipients, patients with cancer, persons with HIV, and patients with other immunocompromising conditions, as some of these patients may be at increased risk of serious complications as a result of COVID-19.

The following sections review the available data on COVID-19 in some of these populations and discuss the specific considerations that clinicians should take into account for the prevention and treatment of SARS-CoV-2 infections in these populations.
Special Considerations in Pregnancy

Last Updated: July 8, 2021

Key Considerations

There is current guidance from the Centers for Disease Control and Prevention, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine on the management of pregnant patients with COVID-19. This section of the COVID-19 Treatment Guidelines complements that guidance. The following are key considerations regarding the management of COVID-19 in pregnancy:

- Pregnant people should be counseled about the increased risk for severe disease from SARS-CoV-2 infection and receive recommendations on ways to protect themselves and their families from infection.
- If hospitalization for COVID-19 is indicated for a pregnant patient, care should be provided in a facility that can conduct maternal and fetal monitoring, when appropriate.
- Management of COVID-19 in pregnant patients should include:
  - Fetal and uterine contraction monitoring based on gestational age, when appropriate
  - Individualized delivery planning
  - A multispecialty, team-based approach that may include consultation with obstetric, maternal-fetal medicine, infectious disease, pulmonary-critical care, and pediatric specialists, as appropriate
- In general, the therapeutic management of pregnant patients with COVID-19 should be the same as for nonpregnant patients. The COVID-19 Treatment Guidelines Panel recommends against withholding treatment for COVID-19 and SARS-CoV-2 vaccination from pregnant or lactating individuals because of theoretical safety concerns (AIII). For details regarding therapeutic recommendations and pregnancy considerations, see General Management of Nonhospitalized Patients With Acute COVID-19 and the individual drug sections.
- Pregnant or lactating patients with COVID-19 and their clinical teams should discuss the use of investigational drugs or drugs that are approved for other indications as treatments for COVID-19. During this shared decision-making process, the patient and the clinical team should consider the safety of the medication for the pregnant or lactating individual and the fetus and the severity of maternal disease. For detailed guidance on using COVID-19 therapeutic agents during pregnancy, please refer to the pregnancy considerations subsections found in the Antiviral Therapy and Immunomodulators sections of these Guidelines.
- The decision to feed the infant breast milk while the patient is receiving therapeutic agents for COVID-19 should be a collaborative effort between the patient and the clinical team, including infant care providers. The patient and the clinical team should discuss the potential benefits of the therapeutic agent and evaluate the potential impact of pausing lactation on the future of breast milk delivery to the infant.

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIA = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

Epidemiology of COVID-19 in Pregnancy

Early in the pandemic, reports of COVID-19 disease acquired during pregnancy were limited to case series or studies that did not compare pregnant patients to age-matched, nonpregnant controls, and these reports were largely reassuring. Subsequent data have indicated that while the overall risk of severe illness is low, COVID-19 is associated with more severe disease in pregnant people than in nonpregnant people.1 There is also an increased risk of poor obstetric outcomes among pregnant people with COVID-19, such as preterm birth.2,3

In November 2020, the Centers for Disease Control and Prevention (CDC) released surveillance data on outcomes in approximately 400,000 reproductive-aged women with symptomatic, laboratory-confirmed COVID-19.1 After adjusting for age, race/ethnicity, and underlying medical conditions, pregnant women had significantly higher rates of intensive care unit (ICU) admission (10.5 vs. 3.9 cases per 1,000 cases;
adjusted risk ratio [aRR] 3.0; 95% CI, 2.6–3.4), mechanical ventilation (2.9 vs. 1.1 cases per 1,000 cases; aRR 2.9; 95% CI, 2.2–3.8), extracorporeal membrane oxygenation (0.7 vs. 0.3 cases per 1,000 cases; aRR 2.4; 95% CI, 1.5–4.0), and death (1.5 vs. 1.2 cases per 1,000 cases; aRR 1.7; 95% CI, 1.2–2.4). The increased risk for severe disease was most significant in women aged 35 to 44 years, who were almost four times as likely to be mechanically ventilated and twice as likely to die as nonpregnant women of the same age.

Notably, among Hispanic women, pregnancy was associated with a risk of death that was 2.4 times higher (95% CI, 1.3–4.3) than the risk observed in nonpregnant Hispanic women. Racial and ethnic disparities were also seen in other reports. Among 8,207 pregnant women with COVID-19 who were reported to CDC, the proportion of those who were reported to be Hispanic (46%) and Black (22%) was higher than the proportion of Hispanic and Black women who gave birth in 2019 (24% and 15%, respectively), suggesting that pregnant people who are Hispanic or Black may be disproportionately affected by SARS-CoV-2 infection.4

In an ongoing systematic review that includes 192 studies to date, maternal factors that were associated with severe disease included increased maternal age (OR 1.83; 95% CI, 1.27–2.63; 3,561 women from 7 studies); a high body mass index (OR 2.37; 95% CI, 1.83–3.07; 3,367 women from 5 studies); any preexisting maternal comorbidity, including chronic hypertension and diabetes (OR 1.81; 95% CI, 1.49–2.20; 2,634 women from 3 studies); pre-eclampsia (OR 4.21; 95% CI, 1.27–14.0; 274 women from 4 studies); and pre-existing diabetes (OR 2.12; 95% CI, 1.62–2.78; 3,333 women from 3 studies).5 Compared with pregnant women and recently pregnant women without COVID-19, pregnant women with COVID-19 were at a higher risk of any instance of preterm birth (OR 1.47; 95% CI, 1.14–1.91; 8,549 women from 18 studies) and stillbirth (OR 2.84; 95% CI, 1.25–6.45; 5,794 women from 9 studies).

An observational cohort study of all pregnant patients at 33 U.S. hospitals with a singleton gestation and a positive result on a SARS-CoV-2 virologic test evaluated maternal characteristics and outcomes across disease severity.6 The data suggested that adverse perinatal outcomes were more common in patients with severe or critical disease than in asymptomatic patients with SARS-CoV-2 infection, including an increased incidence of cesarean delivery (59.6% vs. 34.0% of patients; aRR 1.57; 95% CI, 1.30–1.90), hypertensive disorders of pregnancy (40.4% vs. 18.8%; aRR 1.61; 95% CI, 1.18–2.20), and preterm birth (41.8% vs. 11.9%; aRR 3.53; 95% CI, 2.42–5.14). The perinatal outcomes for those with mild to moderate illness were similar to those observed among asymptomatic patients with SARS-CoV2 infection.

Although vertical transmission of SARS-CoV-2 is possible, current data suggest that it is rare.7 A review of 101 infants born to 100 women with SARS-CoV-2 infection at a single U.S. academic medical center found that 2 infants (2%) had indeterminate SARS-CoV-2 polymerase chain reaction (PCR) results, which were presumed to be positive; however, the infants exhibited no evidence of clinical disease. It is reassuring that the majority of the infants received negative PCR results after rooming with their mothers and breastfeeding directly (the mothers in this study practiced appropriate hand and breast hygiene).

**Managing COVID-19 in Pregnancy**

Pregnant people should be counseled about the increased risk for severe disease from SARS-CoV-2 and the measures they can take to protect themselves and their families from infection. These measures include practicing physical distancing, washing their hands regularly, and wearing a face covering (if indicated). If the patient is not vaccinated, they should be counseled about wearing a face covering and getting vaccinated against SARS-CoV-2 infection. CDC, the American College of Obstetricians and Gynecologists (ACOG), and the Society for Maternal-Fetal Medicine highlight the importance of accessing prenatal care. ACOG provides a list of [frequently asked questions](https://www.covid19treatmentguidelines.nih.gov/) on using telehealth to deliver antenatal care, when appropriate.
ACOG has developed an algorithm to evaluate and manage pregnant outpatients with suspected or laboratory-confirmed SARS-CoV-2 infection. As in nonpregnant patients, SARS-CoV-2 infection in pregnant patients can present as asymptomatic/presymptomatic disease or with a wide range of clinical manifestations, from mild symptoms that can be managed with supportive care at home to severe disease and respiratory failure that requires ICU admission. As in other patients, the illness severity, underlying comorbidities, and clinical status of pregnant patients with symptoms that are compatible with COVID-19 should be assessed to determine whether in-person evaluation for potential hospitalization is needed.

If hospitalization is indicated, care should be provided in a facility that can conduct maternal and fetal monitoring, when appropriate. The management of COVID-19 in the pregnant patient may include:

- Fetal and uterine contraction monitoring based on gestational age, when appropriate
- Individualized delivery planning
- A multispecialty, team-based approach that may include consultation with obstetric, maternal-fetal medicine, infectious disease, pulmonary-critical care, and pediatric specialists, as appropriate.

In general, the recommendations for managing COVID-19 in nonpregnant patients also apply to pregnant patients.

**Therapeutic Management of COVID-19 in the Setting of Pregnancy**

Potentially effective treatments for COVID-19 should not be withheld from pregnant people because of theoretical concerns related to the safety of using those therapeutic agents in pregnancy (AIII).

Pregnant or lactating patients with COVID-19 and their clinical teams should discuss the use of investigational drugs or drugs that are approved for other indications as treatments for COVID-19. During this shared decision-making process, the patient and the clinical team should consider the safety of the medication for the pregnant or lactating individual and the fetus and the severity of maternal disease. For detailed guidance on the use of COVID-19 therapeutic agents during pregnancy, please refer to the pregnancy considerations subsections found in the Antiviral Therapy and Immunomodulators sections of these Guidelines.

The use of anti-SARS-CoV-2 monoclonal antibodies can be considered in pregnant people with COVID-19, especially in those who have additional risk factors for severe disease. There is no pregnancy-specific data on the use of monoclonal antibodies; however, other immunoglobulin G products have been safely used in pregnancy when their use is indicated. Therefore, these products should not be withheld in the setting of pregnancy.

To date, most SARS-CoV-2-related clinical trials have excluded individuals who are pregnant and lactating; in cases where lactating and pregnant individuals have been included in studies, only a small number have been enrolled. This limitation makes it difficult to make evidence-based recommendations on the use of SARS-CoV-2 therapies in these vulnerable patients and potentially limits their COVID-19 treatment options. When possible, pregnant and lactating individuals should not be excluded from clinical trials of therapeutic agents or vaccines for SARS-CoV-2 infection.

**Timing of Delivery**

ACOG provides detailed guidance on the timing of delivery and the risk of vertical transmission of SARS-CoV-2.

In most cases, the timing of delivery should be dictated by obstetric indications rather than maternal diagnosis of COVID-19. For women who had suspected or confirmed COVID-19 early in pregnancy
who recover, no alteration to the usual timing of delivery is indicated.

**Post-Delivery**

The majority of studies have not demonstrated the presence of SARS-CoV-2 in breast milk; therefore, breastfeeding is not contraindicated for people with laboratory-confirmed or suspected SARS-CoV-2 infection. Precautions should be taken to avoid transmission to the infant, including practicing good hand hygiene, wearing face coverings, and performing proper pump cleaning before and after breast milk expression.

The decision to feed the infant breast milk while the patient is receiving therapeutic agents for COVID-19 should be a joint effort between the patient and the clinical team, including infant care providers. The patient and the clinical team should discuss the potential benefits of the therapeutic agent and evaluate the potential impact of pausing lactation on the future of breast milk delivery to the infant.

Specific guidance on the post-delivery management of infants born to mothers with known or suspected SARS-CoV-2 infection, including breastfeeding recommendations, is provided by CDC and the American Academy of Pediatrics, as well as the Special Considerations in Children section in these Guidelines.

**SARS-CoV-2 Vaccine in Pregnancy**

A study that used data from three vaccine safety reporting systems in the United States reported that the frequency of adverse events among 35,691 vaccine recipients who identified as pregnant was similar to the frequency observed among nonpregnant patients. Local injection site pain, nausea, and vomiting were reported slightly more frequently in pregnant people than in nonpregnant people. Other systemic reactions were reported more frequently among nonpregnant vaccine recipients, but the overall reactogenicity profile was similar for pregnant and nonpregnant patients. Surveillance data from 3,958 pregnant patients who were enrolled in CDC’s v-safe Vaccine Pregnancy Registry showed that, among 827 people who completed their pregnancies, there were no obvious safety signals among obstetric or neonatal outcomes when rates of pregnancy loss (spontaneous abortion or stillbirth), preterm birth, congenital anomalies, infants who were small for gestational age, and neonatal death were compared to historic incidences in the peer-reviewed literature. ACOG has published practice guidance on using COVID-19 vaccines in pregnant and lactating people, including a guide to assist clinicians during risk and benefit conversations with pregnant patients.

**References**


Special Considerations in Children

Last Updated: April 21, 2021

### Summary Recommendations

- SARS-CoV-2 infection is generally milder in children than in adults, and a substantial proportion of children with the disease have asymptomatic infection.
- Most children with SARS-CoV-2 infection will not require any specific therapy.
- Children who have a history of medical complexity (e.g., due to neurologic impairment, developmental delays, or genetic syndromes including trisomy 21), obesity, chronic cardiopulmonary disease, or who are immunocompromised, as well as nonwhite children and older teenagers may be at increased risk for severe disease.
- There are limited data on the pathogenesis and clinical spectrum of COVID-19 disease in children. There are no pediatric data from placebo-controlled randomized clinical trials and limited data from observational studies to inform the development of pediatric-specific recommendations for the treatment of COVID-19.

### Specific Therapy for Children

- In the absence of adequate data on the treatment of children with acute COVID-19, recommendations are based on outcome and safety data for adult patients and the child's risk of disease progression.
- Most children with mild or moderate disease can be managed with supportive care alone (AIII).
- **Remdesivir** is recommended for:
  - Hospitalized children aged ≥12 years with COVID-19 who have risk factors for severe disease and have an emergent or increasing need for supplemental oxygen (BIII).
  - Hospitalized children aged ≥16 years with COVID-19 who have an emergent or increasing need for supplemental oxygen regardless of whether they have risks factors for severe disease (BIII).
- In consultation with a pediatric infectious disease specialist, remdesivir can be considered for hospitalized children of all ages with COVID-19 who have an emergent or increasing need for supplemental oxygen (CIII).
- The COVID-19 Treatment Guidelines Panel (the Panel) recommends using dexamethasone for hospitalized children with COVID-19 who require high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (BIII).
- There is insufficient evidence for the Panel to recommend either for or against the use of anti-SARS-CoV-2 monoclonal antibody products for children with COVID-19 who are not hospitalized but who have risk factors for severe disease. Based on adult studies, bamlanivimab plus etesevimab or casirivimab plus imdevimab may be considered on a case-by-case basis for nonhospitalized children who meet Emergency Use Authorization (EUA) criteria for high-risk of severe disease, especially those who meet more than one criterion or are aged ≥16 years. The Panel recommends consulting a pediatric infectious disease specialist in such cases.
- The Panel recommends against the use of convalescent plasma for hospitalized children with COVID-19 who do not require mechanical ventilation, except in a clinical trial (AIII). The Panel recommends against the use of convalescent plasma for pediatric patients with COVID-19 who are mechanically ventilated (AIII). In consultation with a pediatric infectious disease specialist, high-titer convalescent plasma may be considered on a case-by-case basis for hospitalized children who meet the EUA criteria for its use.
- There is insufficient evidence for the Panel to recommend either for or against the use of baricitinib in combination with remdesivir for the treatment of COVID-19 in hospitalized children in whom corticosteroids cannot be used.
- There is insufficient evidence for the Panel to recommend either for or against the use of tocilizumab in hospitalized children with COVID-19 or multisystem inflammatory syndrome in children (MIS-C). The Panel recommends against the use of sarilumab for hospitalized children with COVID-19 or MIS-C, except in a clinical trial (AIII).
- MIS-C is a serious delayed complication of SARS-CoV-2 infection that may develop in a minority of children and young adults.
- Consultation with a multidisciplinary team is recommended when considering and managing immunomodulating therapy for children with MIS-C (AIII). Intravenous immunoglobulin and/or corticosteroids are generally used as first-line therapy, although interleukin-1 antagonists have been used for refractory cases. The optimal choice and combination of immunomodulating therapies have not been definitively established.
**Epidemiology**

Data from the Centers for Disease Control and Prevention (CDC) demonstrate a lower incidence of SARS-CoV-2 infection and severe disease in children than in adults. However, without more systematic testing for children, including for children with mild symptoms as part of contact tracing, or seroprevalence studies, the true burden of pediatric SARS-CoV-2 infection remains unclear. Data on the pathogenesis and disease severity of SARS-CoV-2 infection in children are increasing but are still limited compared to the data in adults. Several large epidemiologic studies suggest that severe manifestations of acute disease are substantially less common in children than in adults. Although only a small percentage of children with COVID-19 will require medical attention, intensive care unit (ICU)-admission rates for hospitalized children are comparable to those for hospitalized adults with COVID-19.

**Clinical Manifestations**

The signs and symptoms of SARS-CoV-2 infection in children may be similar to those in adults, but most children may be asymptomatic or only have a few symptoms. The most common signs and symptoms of COVID-19 in hospitalized children are fever, nausea/vomiting, cough, shortness of breath, and upper respiratory symptoms. Of note, signs and symptoms of COVID-19 may overlap significantly with those of other viral infections, including influenza and other respiratory and enteric viral infections. Although the true incidence of asymptomatic SARS-CoV-2 infection is unknown, asymptomatic infection was reported in up to 45% of children who underwent surveillance testing at the time of hospitalization for a non-COVID-19 indication.

SARS-CoV-2 has been associated with a potentially severe inflammatory syndrome in children and young adults (multisystem inflammatory syndrome in children [MIS-C]), which is discussed below.

**Risk Factors**

Data to clearly establish risk factors for severe COVID-19 in children are limited. Data reported to CDC show lower hospitalization rates and ICU admission rates for children with COVID-19 than for adults with the disease. COVID-19-related hospitalization rates for children were highest in children aged <2 years and higher in Hispanic and Black children than in White children. The majority of hospitalized children with acute COVID-19 had underlying conditions, with obesity, chronic lung disease, and prematurity (data collected only for children aged <2 years) being the most prevalent. Risk factors such as obesity may be more applicable to older teenagers.

In a large study of hospitalized children from the United Kingdom, age <1 month, age 10 to 14 years, and Black race were associated with admission to critical care unit on multivariate analysis. Another large multicenter study from Europe identified male sex, pre-existing medical conditions, and the presence of lower respiratory tract disease at presentation as additional risk factors for ICU admission in multivariable models.

Deaths associated with COVID-19 among those aged <21 years are higher among children aged 10 to 20 years, especially young adults aged 18 to 20 years, as well as among Hispanic, Black, and American Indian/Alaska Native persons. A high proportion of the fatal cases of pediatric COVID-19 are in children with underlying medical conditions, most commonly chronic lung disease, obesity, and neurologic and developmental disorders.
Based on data for adults with COVID-19 and extrapolations from data for non-COVID-19 pediatric respiratory viral infections, severely immunocompromised children and those with underlying cardiopulmonary disease may be at higher risk for severe COVID-19. Initial reports of SARS-CoV-2 infection among pediatric patients with cancer and pediatric solid organ transplant recipients have demonstrated a low frequency of infection and associated morbidity; however, similar reports for other immunocompromised pediatric populations are limited. A few reports have demonstrated a higher prevalence of asthma in pediatric COVID-19 cases, although the association of asthma with severe disease is not clearly defined. Congenital heart disease may be associated with increased risk of severe COVID-19, but the condition has not been consistently identified as a risk factor. Guidance on the treatment of COVID-19 in children endorsed by the Pediatric Infectious Diseases Society specifies additional risk factors to consider when making decisions about antiviral and monoclonal antibody therapy for pediatric patients.

Persistent symptoms after acute COVID-19 have been described in adults, although the incidence of this sequelae in children remains unknown and is an active area of research (see Clinical Spectrum of SARS-CoV-2 Infection). Cardiac imaging studies have described myocardial injury in young athletes who had only mild disease; additional studies are needed to determine long-term cardiac sequelae.

**Vertical Transmission and Infants Born to Mothers with SARS-CoV-2 Infection**

Vertical transmission of SARS-CoV-2 is thought to be rare, but suspected or probable vertical transmission has been described. Initial data on perinatal transmission of SARS-CoV-2 were limited to small case series with conflicting results; some studies demonstrated lack of transmission, whereas others were not able to definitely rule out this possibility. Among 100 women with SARS-CoV-2 infection who delivered 101 infants, only two infants had equivocal reverse transcription polymerase chain reaction (RT-PCR) results that may have reflected SARS-CoV-2 infection even though most of the infants remained with their mothers, in rooms with infection prevention measures in place, and were breast fed.

Infants born to individuals with SARS-CoV-2 infection may have higher risk of poor clinical outcomes than those born to individuals without SARS-CoV-2 infection, although data are conflicting. In a systematic review of case series in pregnant women with confirmed SARS-CoV-2 infection (predominantly from China), the preterm birth rate was 20.1% (57 of 284 births were preterm; 95% CI, 15.8–25.1), the cesarean delivery rate was 84.7% (33 of 392 births were by cesarean delivery; 95% CI, 80.8–87.9), there was no vertical transmission, and the neonatal death rate was 0.3% (1 of 313 neonates died; 95% CI, 0.1–1.8). In a prospective cohort study of 263 infants born in the United States, the rates for preterm births, neonatal ICU admissions, and respiratory disease did not differ between infants born to mothers with and without SARS-CoV-2 infection. A cohort study from Sweden demonstrated that 5-minute Apgar scores and birth weight for gestational age did not differ between infants born to mothers with and without SARS-CoV-2 infection. A systematic review and meta-analysis of studies that included 2,567 pregnancies concluded that SARS-CoV-2-positive mothers were at increased risk of iatrogenic preterm birth. This risk was predominantly due to caesarean sections (21.8% of births) performed due to maternal illness and fear of maternal decompensation. In contrast, there was no increase in the rate of spontaneous preterm birth relative to the expected rate in pregnant individuals without SARS-CoV-2 infection. Finally, a prospective cohort study from the United Kingdom of 66 neonates with SARS-CoV-2 infection found that 3% may have had vertically acquired
infection and 12% had suspected nosocomially acquired infection. Specific guidance on the diagnosis and management of COVID-19 in neonates born to mothers with known or suspected SARS-CoV-2 infection is provided by CDC.

**Treatment Considerations**

There are no results available from clinical trials evaluating treatment for COVID-19 in children, and observational data on the safety or efficacy of drug therapy in children with COVID-19 are extremely limited. More high-quality studies, including randomized trials, are urgently needed. Guidance for the treatment of COVID-19 in children has been published and is mostly extrapolated from recommendations for adults with COVID-19. The older the child and the more severe the disease, the more reasonable it is to follow recommendations for adult patients with COVID-19 (see Therapeutic Management of Nonhospitalized Adults With COVID-19 and Therapeutic Management of Hospitalized Adults With COVID-19). To address the uncertain safety and efficacy of these treatment options, children should be enrolled in clinical trials and multicenter pragmatic trials whenever possible.

The majority of children with mild or moderate COVID-19 will not progress to more severe illness and thus should be managed with supportive care alone (AIII). The risks and benefits of therapy should be assessed based on illness severity, age, and the presence of risk factors outlined above.

**Remdesivir**

Remdesivir is the only drug approved by the Food and Drug Administration (FDA) for the treatment of COVID-19 (see Remdesivir for detailed information). It is approved for the treatment of COVID-19 in hospitalized adult and pediatric patients (aged ≥12 years and weighing ≥40 kg). It is also available through an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in hospitalized pediatric patients weighing 3.5 kg to <40 kg or aged <12 years and weighing ≥3.5 kg. Remdesivir has not been evaluated in clinical trials that include children, and there have been no results from systematic evaluations of pharmacokinetics, efficacy, or toxicity in younger children, although studies are ongoing (see ClinicalTrials.gov). However, based on adult data, the potential benefits of remdesivir are likely to be greater for hospitalized children with COVID-19 who are at higher risk of progression due to older age (i.e., aged ≥16 years) or medical condition than for those without these risk factors. Remdesivir is recommended for hospitalized children aged ≥12 years with COVID-19 who have risk factors for severe disease and have an emergent or increasing need for supplemental oxygen (BIII). Remdesivir is also recommended for hospitalized children aged ≥16 years with COVID-19 who have an emergent or increasing need for supplemental oxygen even in the absence of risk factors (BIII). Remdesivir can be considered for other hospitalized children of all ages with COVID-19 who have an emergent or increasing need for supplemental oxygen in consultation with a pediatric infectious disease specialist (CIII).

**Dexamethasone**

Dexamethasone is recommended for the treatment of hospitalized adults with COVID-19 who require mechanical ventilation or supplemental oxygen through a high-flow device (see Corticosteroids and Therapeutic Management of Hospitalized Adults With COVID-19 for detailed information). The safety and effectiveness of dexamethasone or other corticosteroids for COVID-19 treatment have not been sufficiently evaluated in pediatric patients and thus caution is warranted when extrapolating recommendations for adults to patients aged <18 years. The COVID-19 Treatment Guidelines Panel (the Panel) recommends using dexamethasone for children with COVID-19 who require high-flow oxygen, noninvasive ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) (BIII). It is not routinely recommended for pediatric patients who require only low levels of oxygen support (i.e., via a nasal cannula only). Use of dexamethasone for the treatment of severe COVID-19 in children who are profoundly immunocompromised has not been evaluated, may
be harmful, and therefore should be considered only on a case-by-case basis. If dexamethasone is not available, alternative glucocorticoids such as prednisone, methylprednisolone, or hydrocortisone can be considered. The dexamethasone dosing regimen for pediatric patients is dexamethasone 0.15 mg/kg/dose (maximum dose 6 mg) once daily for up to 10 days.

**Anti-SARS-CoV-2 Monoclonal Antibodies**

Although EUAs have been issued for bamlanivimab plus etesevimab and casirivimab plus imdevimab for the treatment of nonhospitalized, high-risk patients aged ≥12 years and weighing ≥40 kg with mild to moderate COVID-19, there are currently no data available to determine which high-risk pediatric patients defined in the EUAs will likely benefit from these therapies. Consequently, there is insufficient evidence for the Panel to recommend either for or against the use of these monoclonal antibodies in children with COVID-19 who are not hospitalized but are at high risk of severe disease and/or hospitalization. In consultation with a pediatric infectious disease specialist, bamlanivimab plus etesevimab or casirivimab plus imdevimab can be considered on a case-by-case basis for children who meet the EUA criteria, but should not be considered routine care. This recommendation is primarily based on the absence of data assessing efficacy or safety in children or adolescents, limited data with which to identify children at the highest risk of severe COVID-19, as well as the low overall risk of progression to serious disease in children, and the potential risk associated with infusion reactions.

Additional guidance is provided in a recent publication endorsed by the Pediatric Infectious Diseases Society. There are currently no data to support the use of anti-SARS-CoV-2 monoclonal antibodies in hospitalized children for COVID-19. Emerging data regarding the prevalence and clinical significance of SARS-CoV-2 variants, and the efficacy of monoclonal antibodies against variants, may inform the choice of specific anti-SARS-CoV-2 monoclonal antibody therapy in the future.

**Convalescent Plasma**

FDA has also issued an EUA for the use of high-titer convalescent plasma for the treatment of hospitalized patients with COVID-19 (see Convalescent Plasma for detailed information). The safety and efficacy of convalescent plasma have not been evaluated in pediatric patients with COVID-19. There is insufficient evidence for the Panel to recommend either for or against the use of convalescent plasma for the treatment of COVID-19 in either pediatric outpatients or in hospitalized children who do not require mechanical ventilation. The Panel recommends against the use of convalescent plasma for pediatric patients with COVID-19 who are mechanically ventilated (AIII). In consultation with a pediatric infectious disease specialist, convalescent plasma may be considered on a case-by-case basis for children who meet the EUA criteria for its use.

**Baricitinib**

FDA has also issued an EUA for the use of baricitinib in combination with remdesivir in hospitalized adults and children aged ≥2 years with COVID-19 who require supplemental oxygen, invasive mechanical ventilation, or ECMO. The safety and efficacy of baricitinib have not been evaluated in pediatric patients with COVID-19, and pediatric data regarding its use for other conditions are extremely limited. Thus, there is insufficient evidence for the Panel to recommend either for or against the use of baricitinib in combination with remdesivir for the treatment of COVID-19 in hospitalized children in whom corticosteroids cannot be used (see Kinase Inhibitors for detailed information).

**Tocilizumab**

Data on tocilizumab use for the treatment of non-COVID-19 conditions in children are limited to very specific clinical scenarios (e.g., chimeric antigen receptor T cell-related cytokine release syndrome).
The use of tocilizumab for severe cases of acute COVID-19 has been described in pediatric case series.\textsuperscript{14,47} Data on tocilizumab efficacy from trials in adults with COVID-19 are conflicting, and benefit has only been demonstrated in a subset of hospitalized patients (see \textit{Interleukin-6 Inhibitors}). There is insufficient evidence for the Panel to recommend either for or against the use of tocilizumab for hospitalized children with COVID-19 or MIS-C. If used, tocilizumab should be used in combination with dexamethasone. The Panel \textbf{recommends against} the use of sarilumab for hospitalized children with COVID-19 or MIS-C, except in a clinical trial (AIII).

As for other agents outlined in these Guidelines, there is insufficient evidence for the Panel to recommend either for or against the use of specific antivirals or immunomodulatory agents for the treatment of COVID-19 in pediatric patients. Considerations, such as underlying conditions, disease severity, and potential for drug toxicity or drug interactions, may inform decisions on the use of these agents in pediatric patients with COVID-19 on a case-by-case basis. Children should be enrolled in clinical trials evaluating COVID-19 therapies whenever possible. A number of additional drugs are being investigated for the treatment of COVID-19 in adults; refer to the \textit{Antiviral Therapy} and \textit{Immunomodulators} sections to review special considerations for use of these drugs in children and refer to Table 2e and Table 4e for recommendations on pediatric dosing regimens.

**Multisystem Inflammatory Syndrome in Children**

A small subset of children and young adults with SARS-CoV-2 infection develop MIS-C. This immune manifestation is also referred to as pediatric multisystem inflammatory syndrome—temporally associated with SARS-CoV-2 (PMIS-TS), although the case definitions for the syndromes differ slightly. This syndrome was first described in Europe, where previously healthy children with severe inflammation and Kawasaki disease-like features were identified to have current or recent infection with SARS-CoV-2. The clinical spectrum of MIS-C has been described in the United States and is similar to that described for PIMS-TS. MIS-C is consistent with a post-infectious inflammatory syndrome related to SARS-CoV-2.\textsuperscript{48,49} Most MIS-C patients have serologic evidence of previous SARS-CoV-2 infection, but only a minority are RT-PCR positive for SARS-CoV-2 at presentation.\textsuperscript{50,51} The peak incidence of MIS-C lags about 4 weeks behind the peak of acute pediatric COVID-19 hospitalizations. Emerging data suggests that adults may also develop a similar syndrome, multisystem inflammatory syndrome in adults (MIS-A), although it is not clear if this is a postinfectious complication similar to MIS-C.\textsuperscript{50-52} Although risk factors for MIS-C have not been established, in an analysis of MIS-C cases in the United States, most of the children were nonwhite, and obesity was the most common comorbidity.\textsuperscript{53} Unlike in children with acute COVID-19, the majority of children who present with MIS-C do not seem to have underlying comorbid conditions other than obesity.

**Clinical Manifestations**

The current CDC case definition for MIS-C includes:

- An individual aged $<$21 years presenting with fever,\textsuperscript{a} laboratory evidence of inflammation,\textsuperscript{b} and evidence of clinically severe illness requiring hospitalization with multisystem (i.e., more than two) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); \textit{and}
- No alternative plausible diagnoses; \textit{and}
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, antigen test, or serology; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.\textsuperscript{54}

\textsuperscript{a} Fever $>$38.0°C for $\geq$24 hours or report of subjective fever lasting $\geq$24 hours

\textsuperscript{b} Including, but not limited to one or more of the following: an elevated C-reactive protein, erythrocyte sedimentation
rate, fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase, interleukin (IL)-6, or neutrophils, or reduced lymphocytes or albumin levels.

Distinguishing MIS-C from other febrile illnesses in the community setting remains challenging, but presence of persistent fever, multisystem manifestations, and laboratory abnormalities could help early recognition.55 The clinical spectrum of hospitalized cases has included younger children with mucocutaneous manifestations that overlap with Kawasaki disease, older children with more multiorgan involvement and shock, and patients with respiratory manifestations that overlap with acute COVID-19. Patients with MIS-C are often critically ill and up to 80% of children require ICU admission.53 Most patients with MIS-C have markers of cardiac injury or dysfunction, including elevated levels of troponin and brain natriuretic protein.50,51 Echocardiographic findings in these cases include impaired left ventricular function, as well as coronary artery dilations, and rarely, coronary artery aneurysms. Reported mortality rate in the United States for hospitalized children with MIS-C is 1% to 2%. Longitudinal studies are currently ongoing to examine the long-term sequelae of MIS-C.

The pathogenesis of MIS-C is still being elucidated. Differences have been demonstrated between MIS-C and typical Kawasaki disease in terms of epidemiology, cytopenias, cytokine expression, and elevation of inflammatory markers. Immunologic profiling has also shown differences in cytokine expression (tumor necrosis factor alpha and IL-10) between MIS-C and acute COVID-19 in children.56-58

Management

Currently, there are only observational data available to guide treatment for MIS-C. Supportive care remains the mainstay of therapy. There is currently insufficient evidence for the Panel to recommend either for or against any specific therapeutic strategy for the management of MIS-C. MIS-C management decisions should involve a multidisciplinary team of pediatric specialists including experts in intensive care, infectious diseases, cardiology, hematology, and rheumatology. Although no clinical trial data are available, many centers have described the use of immunomodulatory therapy (e.g., intravenous immune globulin [IVIG], corticosteroids, IL-1 and IL-6 inhibitors). The American College of Rheumatology has outlined initial diagnostic and treatment considerations for MIS-C, recommending IVIG and/or corticosteroids as first-tier therapies and other biologic agents as second-line options.48,49,59 An observational study from Europe used propensity matching to compare short-term outcomes in children with MIS-C who were treated initially with IVIG alone or IVIG and methylprednisolone. They observed a lower risk of treatment failure (defined as persistence of fever), more rapid improvement in hemodynamic support, less severe left ventricular dysfunction, and shorter ICU stays among children initially treated with the combination therapy.50 These findings must be confirmed with additional prospective studies. The role of antiviral therapy in MIS-C is not clear, therefore the use of remdesivir should be reserved for patients who have features of acute COVID-19.

References


43. Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization (EUA) of veklury (remdesivir) for hospitalized pediatric patients weighing 3.5 kg to less than 40 kg or hospitalized pediatric patients less than 12 years of age weighing at least 3.5 kg. 2020. Available at: https://www.fda.gov/media/137566/download.


Special Considerations in Adults and Children With Cancer

Last Updated: October 19, 2021

<table>
<thead>
<tr>
<th>Summary Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Given the effectiveness of the COVID-19 vaccines in the general population and the increased risk of severe COVID-19 and mortality in patients with cancer, the COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination for patients with active cancer or patients who are receiving treatment for cancer (AIII).</td>
</tr>
<tr>
<td>• Patients who are receiving active cancer therapy may have suboptimal responses to the current two-dose vaccine series. Because of this, the Centers for Disease Control and Prevention recommends a third dose of an mRNA vaccine for these patients. See the text below for additional information on the criteria for receiving a third dose and the appropriate timing for COVID-19 vaccination in these patients.</td>
</tr>
<tr>
<td>• Patients with cancer are at high risk of progressing to serious COVID-19, and they may be eligible to receive anti-SARS-CoV-2 monoclonal antibodies for treatment or as post-exposure prophylaxis (PEP).</td>
</tr>
<tr>
<td>• The Panel recommends performing molecular diagnostic testing for SARS-CoV-2 in patients with cancer who develop signs and symptoms that suggest COVID-19 (AIII) and in asymptomatic patients prior to procedures that require anesthesia and before initiating cytotoxic chemotherapy and long-acting biologic therapy (BIII).</td>
</tr>
<tr>
<td>• The recommendations for treating COVID-19 in patients with cancer are the same as those for the general population (AIII). See Therapeutic Management of Nonhospitalized Adults With COVID-19 and Therapeutic Management of Hospitalized Adults With COVID-19 for more information.</td>
</tr>
<tr>
<td>• Clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities between drugs that are used to treat COVID-19 and cancer-directed therapies, prophylactic antimicrobials, corticosteroids, and other medications (AIII).</td>
</tr>
<tr>
<td>• Clinicians who are treating COVID-19 in patients with cancer should consult a hematologist or oncologist before adjusting cancer-directed medications (AIII).</td>
</tr>
<tr>
<td>• Decisions about administering cancer-directed therapy during SARS-CoV-2 infection should be made on a case-by-case basis; clinicians should consider the indication for chemotherapy, the goals of care, and the patient’s history of tolerance to the treatment (BIII).</td>
</tr>
</tbody>
</table>

Rating of Recommendations: A = Strong; B = Moderate; C = Optional
Rating of Evidence: I = One or more randomized trials without major limitations; IIa = Other randomized trials or subgroup analyses of randomized trials; IIb = Nonrandomized trials or observational cohort studies; III = Expert opinion

People who are being treated for cancer may be at increased risk of severe COVID-19, and clinical outcomes of COVID-19 are generally worse in people with cancer than in people without cancer. A meta-analysis of 46,499 patients with COVID-19 showed that all-cause mortality (risk ratio 1.66; 95% CI, 1.33–2.07) was higher in patients with cancer, and that patients with cancer were more likely to be admitted to intensive care units (risk ratio 1.56; 95% CI, 1.31–1.87). A patient’s risk of immunosuppression and susceptibility to SARS-CoV-2 infection depend on the type of cancer, the treatments administered, and the stage of disease (e.g., patients who are actively being treated compared to those in remission). In a study that used data from the COVID-19 and Cancer Consortium Registry, patients with cancer who were in remission or who had no evidence of disease were at lower risk of death from COVID-19 than those who were receiving active treatment. It is unclear whether cancer survivors are at increased risk for severe COVID-19 and its complications compared to people without a history of cancer.

Many organizations have outlined recommendations for treating patients with cancer during the COVID-19 pandemic, such as:

• National Comprehensive Cancer Network (NCCN)
• American Society of Hematology (ASH)
This section of the COVID-19 Treatment Guidelines complements these sources and focuses on testing for SARS-CoV-2, managing COVID-19 in patients with cancer, and managing cancer-directed therapies during the COVID-19 pandemic. The optimal management and therapeutic approach to COVID-19 in this population has not yet been defined.

Vaccination for COVID-19 in Patients With Cancer

The clinical trials that evaluated the COVID-19 vaccines that have received Emergency Use Authorizations and/or approval from the Food and Drug Administration (FDA) excluded severely immunocompromised patients. The Advisory Committee on Immunization Practices notes that the authorized COVID-19 vaccines are not live vaccines; therefore, they can be safely administered to immunocompromised people. Given the effectiveness of the COVID-19 vaccines in the general population and the increased risk of severe COVID-19 and mortality in patients with cancer, the COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination for patients with active cancer or patients who are receiving treatment for cancer (AIII). The Centers for Disease Control and Prevention (CDC) recommends a third dose of an mRNA vaccine for patients who are receiving active cancer therapy; this third dose should be administered at least 28 days after the completion of the initial two-dose mRNA COVID-19 vaccine series. ASH and NCCN have provided additional recommendations for administering a third vaccine dose in patients with cancer based on the patient’s tumor type and therapy.

The mRNA vaccines contain polyethylene glycol (PEG), and the Johnson & Johnson (J&J)/Janssen vaccine contains polysorbate. In patients who experience a severe anaphylactic reaction to PEG-asparaginase, consider performing allergy testing for PEG prior to vaccination with either of the mRNA vaccines, or consider using the J&J/Janssen vaccine with precautions.

When determining the timing of COVID-19 vaccination in patients with cancer, clinicians should consider the following factors:

- If possible, patients who are planning to receive chemotherapy should complete vaccination for COVID-19 at least 2 weeks before starting chemotherapy.
- In patients with hematologic malignancy who are undergoing intensive chemotherapy (e.g., induction chemotherapy for acute myelogenous leukemia), vaccination should be delayed until neutrophil recovery.
- Hematopoietic stem cell and chimeric antigen receptor T cell recipients can be offered COVID-19 vaccination starting at least 3 months after therapy.

It is unknown whether the immune response to COVID-19 vaccination can increase the risk of graft-versus-host disease. Studies of patients who received immune checkpoint inhibitors did not report immune-related adverse events in these patients after vaccination.

Decreased immunologic responses to COVID-19 vaccination have been reported in patients who were receiving treatment for solid tumors and hematologic malignancies. The type of therapy has been shown to influence the patient’s response to vaccination. For example, people with chronic lymphocytic leukemia who were treated with Bruton’s tyrosine kinase inhibitors or venetoclax with...
or without anti-CD20 antibodies had extremely low response rates (16.0% and 13.6%, respectively).\textsuperscript{19} In comparison, approximately 80% to 95% of patients with solid tumors showed immunologic responses.\textsuperscript{18,20,21} Currently, it is not known how a third dose of an mRNA vaccine affects response rates in patients with cancer.

Patients with cancer are at high risk of progressing to serious COVID-19, and they may be eligible to receive anti-SARS-CoV-2 monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP).

Vaccination of household members, close contacts, and health care providers who provide care for immunocompromised patients is imperative to protect these patients from infection. All close contacts are strongly encouraged to get vaccinated.

**Testing for SARS-CoV-2 in Patients With Cancer**

The Panel recommends molecular diagnostic testing for SARS-CoV-2 in patients with cancer who develop signs and symptoms of COVID-19 (AIII).

Patients with cancer who are receiving chemotherapy are at risk of developing neutropenia. The NCCN Guidelines for Hematopoietic Growth Factors categorizes cancer treatment regimens based on the patient’s risk of developing neutropenia.\textsuperscript{22} A retrospective study suggests that patients with cancer and neutropenia have a higher mortality rate if they develop COVID-19.\textsuperscript{23} Studies have reported an increased risk of poor clinical outcomes for patients with COVID-19 in the setting of neutropenia and/or during the perioperative period.\textsuperscript{24,25} Because of this, the Panel recommends performing molecular diagnostic testing for SARS-CoV-2 prior to procedures that require anesthesia and before initiating cytotoxic chemotherapy and long-acting biologic therapy (BIII).

**General Guidance on Medical Care for Patients With Cancer During the COVID-19 Pandemic**

Patients with cancer frequently engage with the health care system to receive treatment and supportive care for cancer and/or treatment-related complications. Telemedicine can minimize the need for in-person services and reduce the risk of SARS-CoV-2 exposure. CDC has published a framework to help clinicians decide whether a patient should receive in-person or virtual care during the COVID-19 pandemic; this framework accounts for factors such as the potential harm of delayed care and the degree of SARS-CoV-2 transmission in a patient’s community.\textsuperscript{26} Telemedicine may improve access to providers for medically or socially vulnerable populations, but it could worsen disparities if these populations have limited access to technology. Nosocomial transmission of SARS-CoV-2 to patients and health care workers has been reported.\textsuperscript{27,29} Principles of physical distancing and prevention strategies, including masking patients and health care workers and practicing hand hygiene, apply to all in-person interactions.\textsuperscript{30}

Decisions about treatment regimens, surgery, and radiation therapy for the underlying malignancy should be made on a case-by-case basis, and clinicians should consider the biology of the cancer, the need for hospitalization, the number of clinic visits required, and the anticipated degree of immunosuppression. Additional factors that should be considered include the following:

- If possible, treatment delays should be avoided for curable cancers that have been shown to have worse outcomes when treatment is delayed (e.g., pediatric acute lymphoblastic leukemia).
- When deciding between equally effective treatment regimens, regimens that can be administered orally or those that require fewer infusions are preferred.\textsuperscript{31}
- The potential risks of drug-related lung toxicity (e.g., from using bleomycin or PD-1 inhibitors)
must be balanced with the clinical efficacy of alternative regimens or the risk of delaying care.  

- Preventing neutropenia can decrease the risk of neutropenic fever and the need for emergency department evaluation and hospitalization. Granulocyte colony-stimulating factor (G-CSF) should be given with chemotherapy regimens that have intermediate (10% to 20%) or high (>20%) risks of febrile neutropenia. 

- Cancer treatment regimens that do not affect the outcomes of COVID-19 in patients with cancer may not need to be altered. In a prospective observational study, receipt of immunotherapy, hormonal therapy, or radiotherapy in the month prior to SARS-CoV-2 infection was not associated with an increased risk of mortality among patients with cancer and COVID-19. A retrospective study from Italy evaluated the incidence of SARS-CoV-2 infection in patients with prostate cancer and found that 114 of 37,161 patients (0.3%) who were treated with therapies other than androgen deprivation therapy became infected, compared to 4 of 5,273 patients (0.08%) who were treated with androgen deprivation therapy (OR 4.05; 95% CI, 1.55–10.59). A small cohort study of patients from Finland with prostate cancer did not find an association between androgen deprivation and the incidence of SARS-CoV-2 infection. The viral spike proteins that SARS-CoV-2 uses to enter cells are primed by transmembrane serine protease 2 (TMPRSS2), an androgen-regulated gene. Whether androgen deprivation therapy protects against SARS-CoV-2 infection requires further investigation in larger cohorts or clinical trials. 

- Radiation therapy guidelines suggest increasing the dose per fraction and reducing the number of daily treatments to minimize the number of hospital visits. 

Blood supply shortages will likely continue during the COVID-19 pandemic due to social distancing, cancellation of blood drives, and infection among donors. The FDA has proposed revising the donor criteria to increase the number of eligible donors. In patients with cancer, stricter transfusion thresholds for blood products (e.g., red blood cells, platelets) in asymptomatic patients should be considered. At this time, there is no evidence that COVID-19 can be transmitted through blood products.

**Febrile Neutropenia**

Patients with cancer and febrile neutropenia should undergo molecular diagnostic testing for SARS-CoV-2 and evaluation for other infectious agents; they should also be given empiric antibiotics, as outlined in the NCCN Guidelines. Low-risk febrile neutropenia patients should be treated at home with oral antibiotics or intravenous infusions of antibiotics to limit nosocomial exposure to SARS-CoV-2. Patients with high-risk febrile neutropenia should be hospitalized per standard of care. Empiric antibiotics should be continued per standard of care in patients who test positive for SARS-CoV-2. Clinicians should also continuously evaluate neutropenic patients for emergent infections.

**Treating COVID-19 and Managing Chemotherapy in Patients With Cancer and COVID-19**

Retrospective studies suggest that patients with cancer who were admitted to the hospital with SARS-CoV-2 infection have a high case-fatality rate, with higher rates observed in patients with hematologic malignancies than in those with solid tumors. The recommendations for treating COVID-19 in patients with cancer are the same as those for the general population (AIII). See Therapeutic Management of Nonhospitalized Adults With COVID-19 and Therapeutic Management of Hospitalized Adults With COVID-19 for more information. Patients with cancer are at high risk of progressing to serious COVID-19, and they may be eligible to receive anti-SARS-CoV-2 mAbs as treatment if they develop mild to moderate COVID-19.
Dexamethasone treatment has been associated with a lower mortality rate in patients with COVID-19 who require supplemental oxygen or invasive mechanical ventilation. In patients with cancer, dexamethasone is commonly used to prevent chemotherapy-induced nausea, as a part of tumor-directed therapy, and to treat inflammation associated with brain metastasis. The side effects of dexamethasone are expected to be the same in patients with cancer as in those without cancer. If possible, treatments that are not currently recommended for SARS-CoV-2 infection should be administered as part of a clinical trial, since the safety and efficacy of these agents have not been well-defined in patients with cancer.

The NCCN recommends against using G-CSF and granulocyte-macrophage colony-stimulating factor in patients with cancer and acute SARS-CoV-2 infection who do not have bacterial or fungal infections to avoid the hypothetical risk of increasing inflammatory cytokine levels and pulmonary inflammation. Secondary infections (e.g., invasive pulmonary aspergillosis) have been reported in critically ill patients with COVID-19.

Decisions about administering cancer-directed therapy to patients with acute COVID-19 and those who are recovering from COVID-19 should be made on a case-by-case basis; clinicians should consider the indication for chemotherapy, the goals of care, and the patient’s history of tolerance to the treatment. The optimal duration of time between resolution of infection and initiating or restarting cancer-directed therapy is unclear. Withholding treatment until COVID-19 symptoms have resolved is recommended, if possible. Prolonged viral shedding (detection of SARS-CoV-2 by molecular testing) may occur in patients with cancer, although it is unknown how this relates to infectious virus and how it impacts outcomes. Therefore, there is no role for repeat testing in those recovering from COVID-19, and the decision to restart cancer treatments in this setting should be made on a case-by-case basis. Clinicians who are treating COVID-19 in patients with cancer should consult a hematologist or oncologist before adjusting cancer-directed medications.

**Medication Interactions**

The use of antiviral or immune-based therapies to treat COVID-19 can present additional challenges in patients with cancer. Clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities between drugs that are used to treat COVID-19 and cancer-directed therapies, prophylactic antimicrobials, corticosteroids, and other medications.

Several antineoplastic medications may interact with therapies that are being investigated for COVID-19. For example, tocilizumab can interact with vincristine and doxorubicin. Any COVID-19 therapy that may cause QT prolongation must be used with caution in patients who are being treated with venetoclax, gilteritinib, or tyrosine kinase inhibitor therapy (e.g., nilotinib). Dexamethasone is commonly used as an antiemetic for patients with cancer and is recommended for the treatment of certain patients with COVID-19 (see Therapeutic Management of Hospitalized Adults With COVID-19). Dexamethasone is a weak to moderate cytochrome P450 (CYP) 3A4 inducer; therefore, interactions with any CYP3A4 substrates need to be considered.

**Special Considerations in Children**

Preliminary published reports suggest that pediatric patients with cancer may have milder manifestations of COVID-19 than adult patients with cancer, although larger studies are needed. Guidance on managing children with cancer during the COVID-19 pandemic is available from an international group that received input from the International Society of Paediatric Oncology, the Children’s Oncology Group, St. Jude Global, and Childhood Cancer International. Two publications include guidance for managing specific malignancies, guidance for supportive care, and a summary of web links from expert groups that are relevant to the care of pediatric oncology patients during the COVID-19 pandemic.
Special considerations for using antivirals in immunocompromised children, including those with malignancy, are available in a multicenter guidance statement.57

References


### Summary Recommendations

**Vaccination for COVID-19**
- Given the effectiveness of COVID-19 vaccines in the general population and the increased risk of worse clinical outcomes of COVID-19 in transplant and cellular immunotherapy recipients, the COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination for potential transplant and cellular immunotherapy candidates, potential donors, and recipients (AIII). See the text below for information on the appropriate timing for COVID-19 vaccination in these patients.
- A third dose of an mRNA vaccine (given at least 4 weeks after the second dose) is currently recommended by the Centers for Disease Control and Prevention for solid organ transplant (SOT) recipients who are taking immunosuppressive medications and hematopoietic stem cell transplant (HCT) recipients who are within 2 years of transplantation or who are taking immunosuppressive medications.

**Potential Transplant and Cellular Immunotherapy Candidates**
- The Panel recommends diagnostic molecular testing for SARS-CoV-2 for all potential SOT, HCT, and cellular immunotherapy candidates with signs and symptoms that suggest acute COVID-19 (AIII).
- The Panel recommends following the guidance from medical professional organizations that specialize in providing care for SOT, HCT, or cellular immunotherapy recipients when performing diagnostic molecular testing for SARS-CoV-2 in these patients (AIII).
- If SARS-CoV-2 is detected or if infection is strongly suspected, transplantation should be deferred, if possible (BIII).
- The optimal management and therapeutic approach to COVID-19 in these populations is unknown. At this time, the procedures for evaluating and managing COVID-19 in transplant candidates are the same as those for nontransplant candidates (AIII).
- Additionally, many transplant candidates are at high risk of progressing to serious COVID-19, and they may be eligible to receive anti-SARS-CoV-2 monoclonal antibodies (mAbs) for treatment or post-exposure prophylaxis (PEP).

**Potential Transplant Donors**
- The Panel recommends assessing all potential SOT and HCT donors for signs and symptoms that are associated with COVID-19 according to guidance from medical professional organizations (AIII).
- The Panel recommends performing diagnostic molecular testing for SARS-CoV-2 if symptoms are present (AIII).
- If SARS-CoV-2 is detected or if infection is strongly suspected, donation should be deferred (BIII).

**Transplant and Cellular Immunotherapy Recipients With COVID-19**
- Clinicians should follow the guidelines for evaluating and managing COVID-19 in nontransplant patients when treating transplant and cellular immunotherapy recipients (AIII). See Therapeutic Management of Hospitalized Adults With COVID-19 for more information.
- Immunosuppressed patients with mild to moderate COVID-19 are at high risk of progressing to serious disease, and they may be eligible to receive anti-SARS-CoV-2 mAbs for treatment or PEP.
- The Panel recommends that clinicians who are treating COVID-19 in transplant and cellular immunotherapy patients consult with a transplant specialist before adjusting immunosuppressive medications (AIII).
- When treating COVID-19, clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities with immunosuppressants, prophylactic antimicrobials, and other medications (AIII).

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials without major limitations; Iia = Other randomized trials or subgroup analyses of randomized trials; Iib = Nonrandomized trials or observational cohort studies; III = Expert opinion
Introduction

Treating COVID-19 in solid organ transplant (SOT), hematopoietic stem cell transplant (HCT), and cellular immunotherapy recipients can be challenging due to the presence of coexisting medical conditions, transplant-related cytopenias, and the need for chronic immunosuppressive therapy to prevent graft rejection and graft-versus-host disease. Transplant recipients may also have increased exposure to SARS-CoV-2 given their frequent contact with the health care system. Since immunosuppressive agents modulate several aspects of the host’s immune response, the severity of COVID-19 could potentially be affected by the type and the intensity of the immunosuppressive effect of the agent, as well as by specific combinations of immunosuppressive agents. Some transplant recipients have medical comorbidities that have been associated with more severe cases of COVID-19 and a greater risk of mortality, which makes the impact of transplantation on disease severity difficult to assess.

The International Society for Heart and Lung Transplantation, the American Society of Transplantation, the American Society for Transplantation and Cellular Therapy (ASTCT), and the European Society for Blood and Marrow Transplantation (EBMT) provide guidance for clinicians who are caring for transplant recipients with COVID-19 and guidance on screening potential donors and transplant or cellular immunotherapy candidates. In addition, the American Society of Hematology offers guidance regarding COVID-19 vaccination for transplant and cellular immunotherapy recipients. This section of the COVID-19 Treatment Guidelines complements these sources and focuses on considerations for managing COVID-19 in SOT, HCT, and cellular immunotherapy recipients. The optimal management and therapeutic approach to COVID-19 in these populations is unknown. At this time, the procedures for evaluating and managing COVID-19 in transplant recipients are the same as those for nontransplant patients (AIII). See Therapeutic Management of Hospitalized Adults With COVID-19 for more information. The medications that are used to treat COVID-19 may present different risks and benefits to transplant patients and nontransplant patients.

Vaccination for COVID-19 in Solid Organ Transplant, Hematopoietic Stem Cell Transplant, and Cellular Immunotherapy Candidates, Donors, and Recipients

The clinical trials that evaluated the safety and efficacy of the COVID-19 vaccines excluded severely immunocompromised patients.1-3 The Advisory Committee on Immunization Practices notes that the currently authorized or approved COVID-19 vaccines are not live vaccines; therefore, they can be safely administered to immunocompromised people.4 Compared to healthy vaccine recipients, SOT recipients have a reduced antibody response following a primary two-dose vaccine series of mRNA vaccines.5-7 Among those who had no detectable antibody response to the initial two-dose vaccine series, 33% to 50% of patients developed an antibody response to an additional mRNA vaccine dose.8,9

Given the effectiveness of COVID-19 vaccines in the general population and the increased risk of worse clinical outcomes of COVID-19 in transplant and cellular immunotherapy recipients, the COVID-19 Treatment Guidelines Panel (the Panel) recommends COVID-19 vaccination for potential transplant and cellular immunotherapy candidates, potential donors, and recipients (AIII). Currently, the Centers for Disease Control and Prevention recommends administering an additional dose of vaccine to moderately to severely immunocompromised people at least 28 days after a second dose of an mRNA vaccine.10 This includes people who have:

- Received an SOT and are taking immunosuppressive medications
- Received an HCT within the last 2 years or who are taking immunosuppressive medications

When determining the timing of COVID-19 vaccination in SOT, HCT, and cellular immunotherapy recipients, clinicians should consider the following factors:
• Ideally, SOT candidates should receive COVID-19 vaccines while they are awaiting transplant.
• In general, vaccination should be completed at least 2 weeks prior to SOT or started 1 month after SOT.
• In certain situations, it may be appropriate to delay vaccination until 3 months after SOT, such as when T cell- or B cell-ablative therapy (with antithymocyte globulin or rituximab) is used at the time of transplant.11
• At this time, reducing the dose of immunosuppressants and holding immunosuppressants prior to vaccination are not recommended.
• COVID-19 vaccines can be offered as early as 3 months after a patient receives HCT or chimeric antigen receptor T cell therapy, although the efficacy of the vaccines may be reduced compared to the efficacy observed in the general population.12-14 Patients who are scheduled to receive cytotoxic or B cell-depleting therapies should complete their COVID-19 vaccination prior to initiation or between cycles of cytotoxic or B cell-depleting therapies, if possible.
• After completing COVID-19 vaccination, immunocompromised persons should be advised to continue to exercise precautions to reduce their risk of SARS-CoV-2 exposure and infection (e.g., they should continue wearing a mask, maintain a distance of 6 feet from others, and avoid crowds and poorly ventilated spaces).15

It remains unclear whether the immune responses to COVID-19 vaccines can increase the risk of graft-versus-host disease or other immune-related complications.14,16 Outside of a clinical study, antibody testing is not recommended to assess immunity to SARS-CoV-2 following COVID-19 vaccination in transplant patients. It is currently unknown whether revaccination offers a clinical benefit for people who received COVID-19 vaccines during treatment with immunosuppressive drugs.

Vaccination of household members, close contacts, and health care providers who provide care for immunocompromised patients is imperative to protect immunocompromised patients from infection. All close contacts are strongly encouraged to get vaccinated as soon as possible.

Post-Exposure Prophylaxis for Transplant and Cellular Immunotherapy Recipients

The Food and Drug Administration (FDA) expanded the Emergency Use Authorization (EUA) indication for the anti-SARS-CoV-2 monoclonal antibodies (mAbs) bamlanivimab plus etesevimab and casirivimab plus imdevimab to allow them to be used as post-exposure prophylaxis (PEP) for selected individuals who are at high risk for disease progression. This includes immunocompromised individuals who are not expected to mount an adequate immune response to vaccination. See Prevention of SARS-CoV-2 Infection for more information.

Assessment of SARS-CoV-2 Infection in Transplant and Cellular Immunotherapy Candidates and Donors

The risk of transmission of SARS-CoV-2 from donors to candidates is unknown. The probability that a donor or candidate may have SARS-CoV-2 infection can be estimated by considering the epidemiologic risk, obtaining a clinical history, and testing with molecular techniques. No current testing strategy is sensitive enough or specific enough to totally exclude active infection.

Assessment of Transplant and Cellular Immunotherapy Candidates

Diagnostic molecular testing for SARS-CoV-2 is recommended for all potential SOT candidates with signs and symptoms that suggest acute COVID-19 (AIII). All potential SOT candidates should be assessed for exposure to COVID-19 and clinical symptoms that are compatible with COVID-19 before...
they are called in for transplantation and should undergo diagnostic molecular testing for SARS-CoV-2 shortly before SOT in accordance with guidance from medical professional organizations (AIII).

Clinicians should consider performing diagnostic testing for SARS-CoV-2 in all HCT and cellular immunotherapy candidates who exhibit symptoms. All candidates should also undergo diagnostic molecular testing for SARS-CoV-2 shortly before HCT or cellular immunotherapy (AIII).

**Assessment of Donors**

Living solid organ donors should be counseled on strategies to prevent infection and monitored for exposures and symptoms in the 14 days prior to a scheduled transplant. Living donors should undergo respiratory tract SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) testing within 3 days of donation. Deceased donors should be tested for SARS-CoV-2 infection using an RT-PCR assay of a sample taken from the upper respiratory tract within 72 hours of death; ideally, the test should be performed as close to organ recovery as possible. Deceased donors can be considered for donation if the results are negative (BIII).

Lower respiratory sampling for COVID-19 testing is required for potential lung transplant donors by the United Network for Organ Sharing. The Panel recommends following the guidance from medical professional organizations and assessing all potential HCT donors for exposure to COVID-19 and clinical symptoms that are compatible with COVID-19 before donation (AIII). HCT donors should practice good hygiene and avoid crowded places and large group gatherings during the 28 days prior to donation. Recommendations for screening for HCT donors are outlined in the ASTCT and EBMT guidelines.

**If SARS-CoV-2 Infection Is Detected or Is Strongly Suspected**

If SARS-CoV-2 is detected or if infection is strongly suspected in a potential SOT candidate, transplant should be deferred, if possible (BIII). The optimal disease-free interval before transplantation is not known. The risks of viral transmission should be balanced against the risks to the candidate, such as progression of the underlying disease and risk of mortality if the candidate does not receive the transplant. This decision should be continually reassessed as conditions evolve. Donors for SOT who test positive for SARS-CoV-2 are medically ineligible for donation. For HCT and cellular immunotherapy candidates, current guidelines recommend deferring transplants or immunotherapy procedures, including peripheral blood stem cell mobilization, bone marrow harvest, T cell collection, and conditioning/lymphodepletion in recipients who test positive for SARS-CoV-2 or who have clinical symptoms that are consistent with infection. Final decisions should be made on a case-by-case basis while weighing the risks of delaying or altering therapy for the underlying disease.

**Transplant Recipients With COVID-19**

SOT recipients who are receiving immunosuppressive therapy should be considered to be at increased risk for severe COVID-19. A national survey of 88 U.S. transplant centers conducted between March 24 and 31, 2020, reported that 148 SOT recipients received a diagnosis of SARS-CoV-2 infection (69.6% were kidney recipients, 15.5% were liver recipients, 8.8% were heart recipients, and 6.1% were lung recipients). COVID-19 was mild in 54% of recipients, moderate in 21% of recipients, and 25% of recipients were critically ill. Management strategies varied widely across the transplant centers, including different ways of modifying immunosuppressive therapy and the use of different investigational therapies to treat COVID-19. Initial reports of transplant recipients who were hospitalized with COVID-19 suggest mortality rates of up to 28%.

**Risk of Graft Rejection**

There are concerns that COVID-19 itself may increase the risk for acute rejection. Acute cellular
rejection should not be presumed in SOT recipients without biopsy confirmation, regardless of whether the individual has COVID-19. Similarly, immunosuppressive therapy should be initiated in recipients with or without COVID-19 who have rejection confirmed by a biopsy.21

There are limited data on the incidence and clinical characteristics of SARS-CoV-2 infection in HCT and cellular immunotherapy recipients. Recent data from the Center for International Blood and Marrow Transplant Research demonstrated a mortality rate of approximately 30% within a month of COVID-19 diagnosis among a cohort of 318 HCT recipients.29 This mortality rate was observed in both allogeneic and autologous recipients. Older age (≥50 years), male sex, and receipt of a COVID-19 diagnosis within 12 months of transplantation were associated with a higher risk of mortality among allogeneic recipients. In autologous recipients, patients with lymphoma had a higher risk of mortality than patients who had plasma cell disorder or myeloma.

A smaller study demonstrated a slightly lower mortality rate among HCT and cellular immunotherapy recipients than earlier reports. This study found that the number of comorbidities, the presence of infiltrates on initial chest imaging, and neutropenia were predictors for increased disease severity.30 Additional factors that have been used to determine the clinical severity of other respiratory viral infections include the degree of cytopenia, the intensity of the conditioning regimen, the graft source, the degree of mismatch, and the need for further immunosuppression to manage graft-versus-host disease. Prolonged viral shedding has been described in SOT and HCT recipients; this can have implications for preventing infection and for the timing of therapeutic interventions.31

**Treatment of COVID-19 in Transplant Recipients**

Currently, the antiviral agent remdesivir is the only drug that is approved by the FDA for the treatment of COVID-19. Outpatient transplant recipients who are immunosuppressed or who have certain underlying comorbidities are candidates for the anti-SARS-CoV-2 mAbs that are available through EUAs (see Anti-SARS-CoV-2 Monoclonal Antibodies). Transplant recipients who are hospitalized for reasons other than COVID-19 are also eligible to receive mAb therapy. Transplant recipients who are hospitalized with mild to moderate COVID-19 may be considered for anti-SARS-CoV-2 mAbs that are available through expanded access programs.

Data from a large randomized controlled trial found that a short course of dexamethasone (6 mg once daily for up to 10 days) improved survival in hospitalized patients with COVID-19 who were mechanically ventilated or who required supplemental oxygen.32 Tocilizumab or baricitinib used in combination with dexamethasone is recommended for some patients with severe or critical COVID-19 who exhibit rapid respiratory decompensation (see Interleukin-6 Inhibitors).33-35 The risks and benefits of using dexamethasone in combination with tocilizumab or baricitinib in transplant recipients with COVID-19 who are receiving immunosuppressive therapy are unknown. Because dexamethasone, tocilizumab, and baricitinib are immunosuppressive agents, patients who receive these medications should be closely monitored for secondary infections.

The Panel’s recommendations for the use of remdesivir, dexamethasone, tocilizumab, and baricitinib in patients with COVID-19 can be found in Therapeutic Management of Hospitalized Adults With COVID-19.

A number of other investigational agents and drugs that are approved by the FDA for other indications are being evaluated for the treatment of COVID-19 (e.g., antiviral therapies, COVID-19 convalescent plasma) and its associated complications (e.g., immunomodulators, antithrombotic agents). In general, the considerations for treating COVID-19 in transplant recipients are the same as those for the general population. When possible, treatment should be given as part of a clinical trial. The safety and efficacy of investigational agents and drugs that have been approved by the FDA for other indications are not well-
defined in transplant recipients. Moreover, it is unknown whether concomitant use of immunosuppressive agents to prevent allograft rejection in the setting of COVID-19 affects treatment outcomes.

Clinicians should pay special attention to the potential for drug-drug interactions and overlapping toxicities between treatments for COVID-19 and concomitant medications, such as immunosuppressants that are used to prevent allograft rejection (e.g., corticosteroids, mycophenolate, and calcineurin inhibitors such as tacrolimus and cyclosporine), antimicrobials that are used to prevent opportunistic infections, and other medications. Dose modifications may be necessary for drugs that are used to treat COVID-19 in transplant recipients with pre-existing organ dysfunction. Adjustments to the immunosuppressive regimen should be individualized based on disease severity, the specific immunosuppressants used, the type of transplant, the time since transplantation, the drug concentration, and the risk of graft rejection. Clinicians who are treating COVID-19 in transplant patients should consult a transplant specialist before adjusting immunosuppressive medication (AIII).

Certain therapeutics (e.g., remdesivir, tocilizumab, baricitinib) are associated with elevated levels of transaminases. For liver transplant recipients, the American Association for the Study of Liver Diseases does not consider abnormal liver biochemistries a contraindication to using remdesivir. Close monitoring of liver biochemistries is warranted in patients with COVID-19, especially when they are receiving agents with a known risk of hepatotoxicity.

Calcineurin inhibitors, which are commonly used to prevent allograft rejection, have a narrow therapeutic index. Medications that inhibit or induce cytochrome P450 (CYP) enzymes or P-glycoprotein may put patients who receive calcineurin inhibitors at risk of clinically significant drug-drug interactions, increasing the need for therapeutic drug monitoring and the need to assess for signs of toxicity or rejection. Among the drugs that are commonly used to treat COVID-19, dexamethasone is a moderate inducer of CYP3A4, and interleukin-6 inhibitors may lead to increased metabolism of CYP substrates. Close monitoring of serum concentration of calcineurin inhibitors should be considered when these drugs are used.

Additional details about the adverse effects and drug interactions of antiviral medications and immune-based therapy for COVID-19 are noted in Tables 2e, 3c, and 4e.

References


### Summary Recommendations

**Prevention of COVID-19**
- The COVID-19 Treatment Guidelines Panel (the Panel) recommends that people with HIV receive COVID-19 vaccines regardless of their CD4 T lymphocyte (CD4) cell count or HIV viral load, because the potential benefits outweigh the potential risks (AIII).
- The Advisory Committee on Immunization Practices recommends that people with advanced or untreated HIV who received a two-dose series of an mRNA COVID-19 vaccine should receive a third dose of that vaccine at least 28 days after the second dose. Advanced HIV is defined as people with CD4 counts <200 cells/mm³, a history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV.
- People with HIV who have recently been in close contact with a person with SARS-CoV-2 infection are eligible to receive anti-SARS-CoV-2 monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP); however, in situations where there are logistical or supply constraints for administering mAbs, priority should be given to those with advanced HIV (AIII). See Prevention of SARS-CoV-2 Infection for the specific indications for PEP.

**Diagnosis of COVID-19**
- The Panel recommends using the same approach for diagnosing SARS-CoV-2 infection in people with HIV as in people without HIV (AIII).

**Management of COVID-19**
- Recommendations for the triage, management, and treatment of COVID-19 in people with HIV are generally the same as those for the general population (AIII).
- Nonhospitalized people with HIV and mild to moderate COVID-19 are eligible to receive anti-SARS-CoV-2 mAbs for treatment; however, in situations where there are logistical or supply constraints for administering mAbs, priority should be given to those with advanced HIV (AIII).
- In people with advanced HIV and suspected or documented COVID-19, HIV-associated opportunistic infections should also be considered in the differential diagnosis of febrile illness (AIII).
- When starting treatment for COVID-19 in patients with HIV, clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities among COVID-19 treatments, antiretroviral (ARV) medications, antimicrobial therapies, and other medications (AIII).
- People with HIV should be offered the opportunity to participate in clinical trials that are evaluating agents for the prevention and treatment of SARS-CoV-2 infection.

**Management of HIV**
- People with HIV who develop COVID-19, including those who require hospitalization, should continue their antiretroviral therapy (ART) and opportunistic infection treatment and prophylaxis whenever possible (AIII).
- Clinicians who are treating COVID-19 in people with HIV should consult an HIV specialist before adjusting or switching ARV medications (AIII).
- An ARV regimen should not be switched or adjusted (i.e., by adding ARV drugs to the regimen) for the purpose of preventing or treating SARS-CoV-2 infection (AIII).
- Clinicians should consult an HIV specialist to determine the optimal time to initiate ART in people who present with COVID-19 and a new diagnosis of HIV.

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional  
**Rating of Evidence:** I = One or more randomized trials without major limitations; IIA = Other randomized trials or subgroup analyses of randomized trials; IIB = Nonrandomized trials or observational cohort studies; III = Expert opinion

---

**Introduction**

Approximately 1.2 million people in the United States are living with HIV. Most of these individuals are in care, and many are on antiretroviral therapy (ART) and have well-controlled disease. Similar COVID-19 Treatment Guidelines

Downloaded from [https://www.covid19treatmentguidelines.nih.gov/](https://www.covid19treatmentguidelines.nih.gov/) on 10/26/2021
to COVID-19, HIV disproportionately affects racial and ethnic minorities and people of lower socioeconomic status in the United States; these demographic groups also appear to have a higher risk of poor outcomes with COVID-19.

Information on SARS-CoV-2/HIV coinfection is evolving rapidly. The sections below outline the current state of knowledge regarding preventing and diagnosing SARS-CoV-2 infection in people with HIV, the treatment and clinical outcomes in people with HIV who develop COVID-19, and managing HIV during the COVID-19 pandemic. In addition to these Guidelines, the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents has developed the Interim Guidance for COVID-19 and Persons With HIV.

Clinical Outcomes of COVID-19 in People With HIV

Data are emerging on the clinical outcomes of COVID-19 in people with HIV. In a case series of people with COVID-19 in Europe and the United States, no significant differences were observed in the clinical outcomes of COVID-19 between people with HIV and people who did not have HIV.3-10 For example, the Veterans Aging Cohort Study compared the clinical outcomes for 253 veterans with HIV and COVID-19 and the outcomes for a matched comparator arm of 504 veterans without HIV who developed COVID-19. More than 95% of the participants in this study were male. In this comparison, no differences were found between the outcomes for patients with HIV and those who did not have HIV.11

In contrast, worse outcomes for patients with HIV and COVID-19, including increased COVID-19 mortality rates, have been reported by subsequent cohort studies in the United States, the United Kingdom, and South Africa.12-18 HIV was independently associated with an increased risk of severe and critical COVID-19 in a large World Health Organization platform trial that included data from 24 countries.19 In a multicenter cohort study of 286 patients with HIV and COVID-19 in the United States, lower CD4 T lymphocyte (CD4) cell counts (i.e., <200 cells/mm³) were associated with a higher risk for the composite endpoint of intensive care unit admission, invasive mechanical ventilation, or death. This increased risk was observed even in patients who had achieved virologic suppression of HIV.15 In a large observational cohort study of people with HIV and COVID-19 in the United States, those with CD4 counts <350 cells/mm³ were more likely to be hospitalized, require ventilation, or die. Higher levels of viremia were also associated with worse outcomes.18 In another study of 175 patients with HIV and COVID-19, a low CD4 count or a low CD4 nadir was associated with poor outcomes.16 In a cohort study conducted in New York, people with HIV and COVID-19 had higher rates of hospitalization and mortality than people with COVID-19 who did not have HIV.17

Prevention of COVID-19 in People With HIV

The COVID-19 Treatment Guidelines Panel (the Panel) recommends using the same approach for advising persons with HIV on the strategies to prevent SARS-CoV-2 infection that is used for people without HIV (AIII). There is currently no clear evidence that any antiretroviral (ARV) medications can prevent SARS-CoV-2 infection.

People with HIV should receive COVID-19 vaccines, regardless of their CD4 count or HIV viral load, because the potential benefits outweigh the potential risks (AIII). People with HIV were included in the clinical trials of the two mRNA vaccines and the adenovirus vector vaccine that are currently available through Emergency Use Authorizations (EUAs) and/or approval from the Food and Drug Administration (FDA);20-22 however, the safety and efficacy of these vaccines in people with HIV have not been fully reported. Typically, people with HIV who are on ART and who have achieved virologic suppression respond well to licensed vaccines. Preliminary data from studies that used COVID-19 vaccines in people with HIV confirm that people who are on ART and have normal CD4 counts have good immunologic responses to the vaccines.23-25
On August 12, 2021, the FDA changed the EUAs for the two mRNA vaccines to allow a third dose of an mRNA vaccine to be administered at least 28 days after the second dose to people with advanced or untreated HIV. Advanced HIV is defined as people with CD4 counts <200 cells/mm³, a history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV. Guidance for using these vaccines, including guidance for people with HIV, is available through the Advisory Committee on Immunization Practices. A patient’s HIV status should be kept confidential when administering a vaccine.

People with HIV who have recently been in close contact with a person with SARS-CoV-2 infection are eligible to receive anti-SARS-CoV-2 monoclonal antibodies (mAbs) as post-exposure prophylaxis (PEP); however, in situations where there are logistical or supply constraints for administering mAbs, priority should be given to those with advanced HIV (AIII). See Prevention of SARS-CoV-2 Infection for the specific indications for PEP.

Diagnostic and Laboratory Testing for COVID-19 in People With HIV

Diagnosis of COVID-19 in People With HIV

The Panel recommends using the same approach for diagnosing SARS-CoV-2 infection in people with HIV as in those without HIV (AIII). See Testing for SARS-CoV-2 Infection for more information. There is currently no evidence that the performance characteristics of nucleic acid amplification tests (NAATs) differ in people with and without HIV when diagnosing acute SARS-CoV-2 infection. The Panel recommends against the use of serologic testing as the sole basis for diagnosis of acute SARS-CoV-2 infection (AIII). However, if diagnostic serologic testing is performed in a patient with HIV, the results should be interpreted with caution because cross-reactivity between antibodies to SARS-CoV-2 and HIV has been reported.26

Correlation of CD4 Count in People With HIV and COVID-19

The normal range for CD4 counts in healthy adults is about 500 to 1,600 cells/mm³. People with HIV who have a CD4 count of ≥500 cells/mm³ have similar cellular immune function to those without HIV. In people with HIV, a CD4 count <200 cells/mm³ meets the definition for AIDS. For patients on ART, the hallmark of treatment success is plasma HIV RNA below the level of detection by a polymerase chain reaction assay. Lymphopenia is a common laboratory finding in patients with COVID-19; in patients with HIV, clinicians should note that CD4 counts obtained during acute COVID-19 may not accurately reflect the patient’s HIV disease stage.

There have been some reports of people with advanced HIV who have presented with COVID-19 and another coinfection, including Pneumocystis jirovecii pneumonia.27,28 In patients with advanced HIV who have suspected or laboratory-confirmed SARS-CoV-2 infection, clinicians should consider a broader differential diagnosis for clinical symptoms and consider consulting an HIV specialist (AIII).

Clinical Presentation of COVID-19 in People With HIV

It is currently unknown whether people with HIV have a higher incidence of SARS-CoV-2 infection or a higher rate of progression to symptomatic disease than the general population. Approximately 50% of people with HIV in the United States are aged >50 years,29 and many have comorbidities that are associated with more severe cases of COVID-19. These comorbidities include hypertension, diabetes mellitus, cardiovascular disease, tobacco use disorder, chronic lung disease, chronic liver disease, and cancer.30

There are a number of case reports and case series that describe the clinical presentation of COVID-19 in people with HIV.3-10,31,32 These studies indicate that the clinical presentation of COVID-19 is similar in

Downloaded from https://www.covid19treatmentguidelines.nih.gov/ on 10/26/2021
people with and without HIV. Most of the published reports describe populations in which most of the individuals with HIV are on ART and have achieved virologic suppression. Consequently, the current understanding of the impact of COVID-19 in those with advanced HIV who have low CD4 counts or persistent HIV viremia is limited.

Management of COVID-19 in People With HIV

Recommendations for the triage and management of COVID-19 in people with HIV are the same as those for the general population (AIII).

The treatment of COVID-19 in persons with HIV is the same as for those without HIV (AIII). Nonhospitalized people with HIV and mild to moderate COVID-19 are eligible to receive anti-SARS-CoV-2 mAbs for treatment; however, in situations where there are logistical or supply constraints for administering mAbs, priority should be given to those with advanced HIV (AIII). See Prevention of SARS-CoV-2 Infection for more information. In hospitalized patients, the appropriate treatment strategy depends on disease severity (see Therapeutic Management of Hospitalized Adults With COVID-19).

When starting treatment for COVID-19 in patients with HIV, clinicians should pay careful attention to potential drug-drug interactions and overlapping toxicities among COVID-19 treatments, ARV medications, antimicrobial therapies, and other medications (AIII). Both tocilizumab and dexamethasone, which are recommended for some patients with severe or critical COVID-19, are immunosuppressive agents. The safety of using these drugs in immunocompromised patients, including those with advanced HIV, has not been studied. Therefore, patients with advanced HIV who are receiving these drugs should be closely monitored for secondary infections. Dexamethasone is a dose-dependent inducer of cytochrome P450 3A4, and it could potentially lower the levels of certain coadministered ARV drugs. More than a single dose of dexamethasone is not recommended for patients who are receiving rilpivirine as part of their ARV regimen. Clinicians should consult an HIV specialist before administering dexamethasone to these patients. It is currently unknown whether administering ≤10 days of dexamethasone impacts the clinical efficacy of other ARV drugs. Patients with HIV who are receiving dexamethasone as treatment for COVID-19 should follow up with their HIV providers to assess their virologic response.

Although some ARV drugs are being studied for the prevention and treatment of COVID-19, no agents have been shown to be effective.

People with HIV should be offered the opportunity to participate in clinical trials of vaccines and potential treatments for COVID-19. A variety of immunomodulatory therapies are prescribed empirically or administered as part of a clinical trial to treat severe COVID-19. The data on whether these medications are safe to use in patients with HIV are lacking. If a medication has been shown to reduce the mortality of patients with COVID-19 in the general population, it should also be used to treat COVID-19 in patients with HIV, unless data indicate that the medication is not safe or effective in this population.

Managing HIV in People With SARS-CoV-2/HIV Coinfection

Below are some general considerations regarding the management of HIV in people with SARS-CoV-2/HIV coinfection.

- Whenever possible, ART and opportunistic infection prophylaxis should be continued in a patient with HIV who develops COVID-19, including in those who require hospitalization (AIII). Treatment interruption may lead to rebound viremia, and, in some cases, the emergence of drug resistance. If the appropriate ARV drugs are not on the hospital’s formulary, administer medications from the patient’s home supplies, if available.
•Clinicians who are treating COVID-19 in people with HIV should consult an HIV specialist before adjusting or switching a patient’s ARV medications. An ARV regimen should not be switched or adjusted (i.e., by adding ARV drugs to the regimen) for the purpose of preventing or treating SARS-CoV-2 infection (AIII). Many drugs, including some ARV agents (e.g., lopinavir/ritonavir, boosted darunavir, tenofovir disoproxil fumarate/emtricitabine), have been or are being evaluated in clinical trials or are prescribed off-label to treat or prevent SARS-CoV-2 infection. To date, lopinavir/ritonavir and darunavir/cobicistat have not been found to be effective (see Lopinavir/Ritonavir and Other HIV Protease Inhibitors).33,34 Two retrospective studies have suggested that tenofovir disoproxil fumarate/emtricitabine may play a role in preventing SARS-CoV-2 acquisition or hospitalization or death associated with COVID-19; however, the significance of these findings is unclear, as neither study adequately controlled for confounding variables such as age and comorbidities.12,32

•For patients who are taking an investigational ARV medication as part of their ARV regimen, arrangements should be made with the investigational study team to continue the medication, if possible.

•For critically ill patients who require tube feeding, some ARV medications are available in liquid formulations, and some ARV pills may be crushed. Clinicians should consult an HIV specialist and/or pharmacist to assess the best way to continue an effective ARV regimen for a patient with a feeding tube. Information may be available in the drug product label or in this document from Toronto General Hospital.

•For people who present with COVID-19 and have either a new diagnosis of HIV or a history of HIV but are not taking ART, the optimal time to start or restart ART is currently unknown. For people with HIV who have not initiated ART or who have been off therapy for >2 weeks before presenting with COVID-19, the Panel recommends consulting an HIV specialist about initiating or reinitiating ART as soon as clinically feasible. If ART is initiated, maintaining treatment and linking patients to HIV care upon hospital discharge is critical. If an HIV specialist is not available, clinical consultation is available by phone through the National Clinical Consultation Center, Monday through Friday, 9 am to 8 pm EST.

References


Influenza and COVID-19

Last Updated: October 22, 2020

**Summary Recommendations**

**Influenza Vaccination**
- Although data are lacking on influenza vaccination for persons with COVID-19, on the basis of practice for other acute respiratory infections, the Panel recommends that persons with COVID-19 should receive an inactivated influenza vaccine (BIII). The Centers for Disease Control and Prevention (CDC) has provided guidance on the timing of influenza vaccination for inpatients and outpatients with COVID-19 (see Interim Guidance for Routine and Influenza Immunization Services During the COVID-19 Pandemic).

**Diagnosis of Influenza and COVID-19 When Influenza Viruses and SARS-CoV-2 Are Cocirculating**
- Only testing can distinguish between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus infections and identify SARS-CoV-2 and influenza virus coinfection.
- When SARS-CoV-2 and influenza viruses are cocirculating, the Panel recommends testing for both viruses in all hospitalized patients with acute respiratory illness (AIII).
- When SARS-CoV-2 and influenza viruses are cocirculating, the Panel recommends influenza testing in outpatients with acute respiratory illness if the results will change clinical management of the patient (BIII).
- Testing for other pathogens should be considered depending on clinical circumstances, especially in patients with influenza in whom bacterial superinfection is a well-recognized complication.
- See the CDC Information for Clinicians on Influenza Virus Testing and the Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for more information.

**Antiviral Treatment of Influenza When Influenza Viruses and SARS-CoV-2 Are Cocirculating**
- The treatment of influenza is the same in all patients regardless of SARS-CoV-2 coinfection (AIII).
- The Panel recommends that hospitalized patients be started on empiric treatment for influenza with oseltamivir as soon as possible without waiting for influenza testing results (AIIb).
- Antiviral treatment of influenza can be stopped when influenza has been ruled out by nucleic acid detection assay in upper respiratory tract specimens for nonintubated patients and in both upper and lower respiratory tract specimens for intubated patients.
- For influenza treatment in hospitalized and non-hospitalized patients, see the CDC and IDSA recommendations on antiviral treatment of influenza.

**Rating of Recommendations:** A = Strong; B = Moderate; C = Optional

**Rating of Evidence:** I = One or more randomized trials without major limitations; IIA = Other randomized trials or subgroup analyses of randomized trials; IIB = Nonrandomized trials or observational cohort studies; III = Expert opinion

**Introduction**

Influenza activity in the United States during the 2020–2021 influenza season is difficult to predict and could vary geographically and by the extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) community mitigation measures. During early 2020, sharp declines in influenza activity coincided with implementation of SARS-CoV-2 control measures in the United States and several Asian countries. Very low influenza virus circulation was observed in Australia, Chile, and South Africa during the typical Southern Hemisphere influenza season in 2020. Clinicians should monitor local influenza and SARS-CoV-2 activity (e.g., by tracking local and state public health surveillance data and testing performed at health care facilities) to inform evaluation and management of patients with acute respiratory illness.

**Influenza Vaccination**

There are no data on the safety, immunogenicity, or effectiveness of influenza vaccines in patients...
with mild COVID-19 or those who are recovering from COVID-19. Therefore, the optimal timing for influenza vaccination in these patients is unknown. The safety and efficacy of vaccinating persons who have mild illnesses from other etiologies have been documented. On the basis of practice following other acute respiratory infections, the Panel recommends that persons with COVID-19 should receive an inactivated influenza vaccine (BIII). The Centers for Disease Control and Prevention (CDC) has provided guidance on the timing of influenza vaccination for inpatients and outpatients with COVID-19 (see Interim Guidance for Routine and Influenza Immunization Services During the COVID-19 Pandemic). It is not known whether dexamethasone or other immunomodulatory therapies for COVID-19 will affect the immune response to influenza vaccine. However, despite this uncertainty, as long as influenza viruses are circulating, an unvaccinated person with COVID-19 should receive the influenza vaccine once they have substantially improved or recovered from COVID-19. See influenza vaccine recommendations from CDC and the Advisory Committee on Immunization Practices.

Clinical Presentation of Influenza Versus COVID-19

The signs and symptoms of uncomplicated, clinically mild influenza overlap with those of mild COVID-19. Ageusia and anosmia can occur with both diseases, but these symptoms are more common with COVID-19 than with influenza. Fever is not always present in patients with either disease, particularly in patients who are immunosuppressed or elderly. Complications of influenza and COVID-19 can be similar, but the onset of influenza complications and severe disease typically occurs within a week of illness onset whereas the onset of severe COVID-19 usually occurs in the second week of illness. Because of the overlap in signs and symptoms, when SARS-CoV-2 and influenza viruses are cocirculating, diagnostic testing for both viruses in people with an acute respiratory illness is needed to distinguish between SARS-CoV-2 and influenza virus, and to identify SARS-CoV-2 and influenza virus coinfection. Coinfection with influenza A or B viruses and SARS-CoV-2 has been described in case reports and case series, but the frequency, severity, and risk factors for coinfection with these viruses versus for infection with either virus alone are unknown.

Which Patients Should be Tested for SARS-CoV-2 and influenza?

When influenza viruses and SARS-CoV-2 are cocirculating in the community, SARS-CoV-2 testing and influenza testing should be performed in all patients hospitalized with suspected COVID-19 or influenza (see Testing for SARS-CoV-2 Infection) (AIII). When influenza viruses and SARS-CoV-2 are cocirculating in the community, SARS-CoV-2 testing should be performed in outpatients with suspected COVID-19, and influenza testing can be considered in outpatients with suspected influenza if the results will change clinical management of the illness (BIII). Several multiplex assays that detect SARS-CoV-2 and influenza A and B viruses have received Food and Drug Administration Emergency Use Authorization and can provide results in 15 minutes to 8 hours on a single respiratory specimen. For information on available influenza tests, including clinical algorithms for testing of patients when SARS-CoV-2 and influenza viruses are cocirculating, see the CDC Information for Clinicians on Influenza Virus Testing and recommendations of the Infectious Diseases Society of America (IDSA) on the use of influenza tests and interpretation of testing results.

Which Patients Should Receive Antiviral Treatment of Influenza?

When SARS-CoV-2 and influenza viruses are cocirculating in the community, patients who require hospitalization and are suspected of having either or both viral infections should receive influenza antiviral treatment with oseltamivir as soon as possible without waiting for influenza testing results (AIIb). Treatment for influenza is the same for all patients regardless of SARS-CoV-2 coinfeciton (AIII). See the CDC Influenza Antiviral Medications: Summary for Clinicians, including clinical algorithms for antiviral treatment of patients with suspected or confirmed influenza when SARS-CoV-2...
and influenza viruses are cocirculating, and the IDSA Clinical Practice Guidelines recommendations on antiviral treatment of influenza.

If a diagnosis of COVID-19 or another etiology is confirmed and if the result of an influenza nucleic acid detection assay from an upper respiratory tract specimen is negative:

- **In a Patient Who is Not Intubated:** Antiviral treatment for influenza can be stopped.
- **In a Patient Who is Intubated:** Antiviral treatment for influenza should be continued and if a lower respiratory tract specimen (e.g., endotracheal aspirate) can be safely obtained, it should be tested by influenza nucleic acid detection. If the lower respiratory tract specimen is also negative, influenza antiviral treatment can be stopped.

### Treatment Considerations for Hospitalized Patients With Suspected or Confirmed SARS-CoV-2 and Influenza Virus Coinfection

- Corticosteroids, which may be used for the treatment of COVID-19, may prolong influenza viral replication and viral RNA detection and may be associated with poor outcomes.\(^{14,15}\)
- Oseltamivir has no activity against SARS-CoV-2.\(^{16}\) Oseltamivir does not have any known interactions with remdesivir.
- Standard-dose oseltamivir is well absorbed even in critically ill patients. For patients who cannot tolerate oral or enterically administered oseltamivir (e.g., because of gastric stasis, malabsorption, or gastrointestinal bleeding), intravenous peramivir is an option.\(^{14}\) There are no data on peramivir activity against SARS-CoV-2.
- CDC does not recommend inhaled zanamivir and oral baloxavir for the treatment of influenza in hospitalized patients because of insufficient safety and efficacy data (see the CDC Influenza Antiviral Medications: Summary for Clinicians). There are no data on zanamivir activity against SARS-CoV-2. Baloxavir has no activity against SARS-CoV-2.\(^{16}\)
- Based upon limited data, the co-occurrence of community-acquired secondary bacterial pneumonia with COVID-19 appears to be infrequent and may be more common with influenza.\(^{17,18}\) Typical bacterial causes of community-acquired pneumonia with severe influenza are *Staphylococcus aureus* (methicillin-resistant *S. aureus* [MRSA] and methicillin-susceptible *S. aureus* [MSSA]), *Streptococcus pneumoniae*, and group A *Streptococcus*.\(^{14}\)
- Patients with COVID-19 who develop new respiratory symptoms with or without fever or respiratory distress, and without a clear diagnosis, should be evaluated for the possibility of nosocomial influenza.

### References


